Credit Suisse’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.43M | Hold |
83,635
| – | – | ﹤0.01% | 1725 |
|
|
2023
Q4 | $2.3M | Buy |
83,635
+10,941
| +15% | +$250K | ﹤0.01% | 1799 |
|
|
2023
Q3 | $1.63M | Sell |
72,694
-16,831
| -19% | -$626K | ﹤0.01% | 1960 |
|
|
2023
Q2 | $3.64M | Buy |
89,525
+24,275
| +37% | +$1.19M | ﹤0.01% | 1543 |
|
|
2023
Q1 | $3.16M | Buy |
65,250
+4,059
| +7% | +$186K | ﹤0.01% | 1606 |
|
|
2022
Q4 | $2.34M | Sell |
61,191
-1,351
| -2% | -$56.2K | ﹤0.01% | 1780 |
|
|
2022
Q3 | $3.14M | Sell |
62,542
-4,605
| -7% | -$226K | ﹤0.01% | 1551 |
|
|
2022
Q2 | $2.69M | Sell |
67,147
-3,766
| -5% | -$132K | ﹤0.01% | 1700 |
|
|
2022
Q1 | $2.65M | Buy |
70,913
+9,437
| +15% | +$364K | ﹤0.01% | 1892 |
|
|
2021
Q4 | $2.45M | Sell |
61,476
-3,998
| -6% | -$153K | ﹤0.01% | 2632 |
|
|
2021
Q3 | $2.44M | Sell |
65,474
-17,957
| -22% | -$738K | ﹤0.01% | 2673 |
|
|
2021
Q2 | $3.53M | Buy |
83,431
+14,306
| +21% | +$613K | ﹤0.01% | 2385 |
|
|
2021
Q1 | $3.27M | Sell |
69,125
-38,060
| -36% | -$2.26M | ﹤0.01% | 2443 |
|
|
2020
Q4 | $6.54M | Buy |
107,185
+19,168
| +22% | +$1.13M | ﹤0.01% | 1885 |
|
|
2020
Q3 | $4.12M | Sell |
88,017
-17,069
| -16% | -$840K | ﹤0.01% | 1921 |
|
|
2020
Q2 | $5.33M | Buy |
105,086
+23,380
| +29% | +$1.15M | ﹤0.01% | 1669 |
|
|
2020
Q1 | $3.65M | Sell |
81,706
-17,574
| -18% | -$885K | ﹤0.01% | 1737 |
|
|
2019
Q4 | $4.77M | Sell |
99,280
-400,014
| -80% | -$17M | ﹤0.01% | 1916 |
|
|
2019
Q3 | $16.9M | Buy |
499,294
+462,858
| +1,270% | +$20.1M | 0.01% | 1016 |
|
|
2019
Q2 | $1.64M | Sell |
36,436
-8,425
| -19% | -$333K | ﹤0.01% | 2595 |
|
|
2019
Q1 | $1.69M | Buy |
44,861
+17,182
| +62% | +$577K | ﹤0.01% | 2494 |
|
|
2018
Q4 | $951K | Sell |
27,679
-54,653
| -66% | -$1.97M | ﹤0.01% | 2812 |
|
|
2018
Q3 | $3.87M | Buy |
82,332
+40,549
| +97% | +$1.68M | ﹤0.01% | 1870 |
|
|
2018
Q2 | $1.41M | Sell |
41,783
-17,688
| -30% | -$552K | ﹤0.01% | 2758 |
|
|
2018
Q1 | $1.61M | Buy |
59,471
+20,639
| +53% | +$523K | ﹤0.01% | 2594 |
|
|
2017
Q4 | $647K | Sell |
38,832
-18,834
| -33% | -$319K | ﹤0.01% | 3288 |
|
|
2017
Q3 | $1.15M | Buy |
57,666
+11,975
| +26% | +$234K | ﹤0.01% | 2990 |
|
|
2017
Q2 | $838K | Sell |
45,691
-57,584
| -56% | -$776K | ﹤0.01% | 2805 |
|
|
2017
Q1 | $1.02M | Buy |
103,275
+47,955
| +87% | +$580K | ﹤0.01% | 2853 |
|
|
2016
Q4 | $604K | Buy |
55,320
+21,131
| +62% | +$222K | ﹤0.01% | 3341 |
|
|
2016
Q3 | $480K | Sell |
34,189
-4,197
| -11% | -$34.1K | ﹤0.01% | 3446 |
|
|
2016
Q2 | $269K | Buy |
38,386
+2,883
| +8% | +$21.1K | ﹤0.01% | 3744 |
|
|
2016
Q1 | $228K | Sell |
35,503
-1,043
| -3% | -$18.1K | ﹤0.01% | 3636 |
|
|
2015
Q4 | $1.18M | Sell |
36,546
-12,775
| -26% | -$376K | ﹤0.01% | 2687 |
|
|
2015
Q3 | $1.32M | Sell |
49,321
-35,426
| -42% | -$1.52M | ﹤0.01% | 2576 |
|
|
2015
Q2 | $4.08M | Sell |
84,747
-1,101,744
| -93% | -$64.3M | ﹤0.01% | 1917 |
|
|
2015
Q1 | $72.2M | Buy |
1,186,491
+3,314
| +0.3% | +$202K | 0.07% | 283 |
|
|
2014
Q4 | $61.3M | Sell |
1,183,177
-379,669
| -24% | -$16.7M | 0.05% | 386 |
|
|
2014
Q3 | $68.8M | Sell |
1,562,846
-710,399
| -31% | -$22.2M | 0.06% | 361 |
|
|
2014
Q2 | $59.4M | Buy |
2,273,245
+4,346
| +0.2% | +$93K | 0.05% | 412 |
|
|
2014
Q1 | $59.3M | Buy |
2,268,899
+4,172
| +0.2% | +$112K | 0.06% | 351 |
|
|
2013
Q4 | $38.4M | Buy |
2,264,727
+7,352
| +0.3% | +$129K | 0.03% | 511 |
|
|
2013
Q3 | $48.4M | Buy |
+2,257,375
| New | +$39.2M | 0.05% | 355 |
|
Other funds holding PTCT
RI
AC
CCM
CAC
Credit Suisse's PTCT Position: Q1 2024 in Review
Credit Suisse held its PTC Therapeutics (PTCT) position steady in Q1 2024 at 83,635 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1725.
Credit Suisse first reported a position in PTCT in Q3 2013 and has held it in 43 quarters since. The position peaked at $72.2M in Q1 2015. 184 funds tracked by Wall St. Rank hold PTCT as of Q1 2024.
- Credit Suisse held 83,635 shares of PTC Therapeutics worth $2.43M as of Q1 2024.
- Credit Suisse left its PTC Therapeutics share count unchanged in Q1 2024.
- PTC Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1725 holding.
- Credit Suisse first reported a position in PTC Therapeutics in Q3 2013 and has held it in 43 quarters since.
- Credit Suisse's PTC Therapeutics position peaked at $72.2M in Q1 2015.
- 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.